These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 9804453)
1. Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal. Zhang Y; Singh VK; Yang VC ASAIO J; 1998; 44(5):M368-73. PubMed ID: 9804453 [TBL] [Abstract][Full Text] [Related]
2. Poly-L-lysine amplification of protamine immobilization and heparin adsorption. Zhang Y; Singh VK; Yang VC J Biomed Mater Res; 1998 Nov; 42(2):182-7. PubMed ID: 9773814 [TBL] [Abstract][Full Text] [Related]
3. Strategies for improving the functionality of an affinity bioreactor. Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511 [TBL] [Abstract][Full Text] [Related]
4. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction. Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812 [TBL] [Abstract][Full Text] [Related]
5. A protamine filter for extracorporeal blood heparin removal. Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594 [TBL] [Abstract][Full Text] [Related]
6. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy. Yang VC; Teng CL; Kim JS Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582 [TBL] [Abstract][Full Text] [Related]
7. Development of protamine hollow-fiber device for extracorporeal heparin removal. Liang JF; Emregul E; Yang VC Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818 [TBL] [Abstract][Full Text] [Related]
8. Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling. Byun Y; Wang T; Kim JS; Yang VC ASAIO J; 1996; 42(5):M782-7. PubMed ID: 8944989 [TBL] [Abstract][Full Text] [Related]
9. A novel approach to anticoagulation control. Kim JS; Vincent C; Teng CL; Wakefield TW; Yang VC ASAIO Trans; 1989; 35(3):644-6. PubMed ID: 2597555 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass. Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162 [TBL] [Abstract][Full Text] [Related]
11. Protamine immobilization and heparin adsorption on the protamine-bound cellulose fiber membrane. Kim JS; Yang AJ; Yang VC Biotechnol Bioeng; 1992 Feb; 39(4):450-6. PubMed ID: 18600967 [TBL] [Abstract][Full Text] [Related]
12. A method for extracorporeal heparin removal from blood by affinity chromatography. Hou KC; Roy S; Zaniewski R; Shumway E Artif Organs; 1990 Dec; 14(6):436-42. PubMed ID: 2281993 [TBL] [Abstract][Full Text] [Related]
13. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass. Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577 [TBL] [Abstract][Full Text] [Related]
14. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine. Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661 [TBL] [Abstract][Full Text] [Related]
15. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation. Yang VC; Port FK; Kim JS; Teng CL; Till GO; Wakefield TW Anesthesiology; 1991 Aug; 75(2):288-97. PubMed ID: 1859016 [TBL] [Abstract][Full Text] [Related]
16. Can protamine be used during perfusion with heparin surface coated equipment? von Segesser LK; Gyurech DD; Schilling JJ; Marquardt K; Turina MI ASAIO J; 1993; 39(3):M190-4. PubMed ID: 8268526 [TBL] [Abstract][Full Text] [Related]
17. Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Fabbri LP; Nucera M; Al Malyan M; Becchi C Acta Anaesthesiol Scand; 2010 Jan; 54(1):92-7. PubMed ID: 19650808 [TBL] [Abstract][Full Text] [Related]
18. Molecularly designed surfaces for blood deheparinization using an immobilized heparin-binding peptide. Martins MC; Curtin SA; Freitas SC; Salgueiro P; Ratner BD; Barbosa MA J Biomed Mater Res A; 2009 Jan; 88(1):162-73. PubMed ID: 18286636 [TBL] [Abstract][Full Text] [Related]
19. Heparin removal from blood using poly(L-lysine) immobilized hollow fiber. Ma X; Mohammad SF; Kim SW Biotechnol Bioeng; 1992 Aug; 40(4):530-6. PubMed ID: 18601148 [TBL] [Abstract][Full Text] [Related]
20. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation. Chang LC; Lee HF; Chung MJ; Yang VC Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]